Skip to main content
Clinical Trials/EUCTR2018-000677-77-BE
EUCTR2018-000677-77-BE
Active, not recruiting
Phase 1

ovel strategies in weight loss in women with polycystic ovary syndrome: does the gut microbiome play a role?

niversity Hospital Leuven0 sites60 target enrollmentMarch 29, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
overweight and obese women with polycystic ovary syndrome (PCOS) at risk for metabolic syndrome
Sponsor
niversity Hospital Leuven
Enrollment
60
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 29, 2018
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
niversity Hospital Leuven

Eligibility Criteria

Inclusion Criteria

  • Women aged between 18 and 40 years, with PCOS presenting anovulation, hyperandrogenism and polycystic ovarian morphology and who are at risk for metabolic syndrome:
  • oBMI \= 27 kg/m2 and one of the risk factors of metabolic syndrome according to the International Diabetes Federation (IDF) consensus worldwide definition of the metabolic syndrome 2006
  • oBMI \= 30 kg/m2
  • and who have no known inflammatory bowel disease or auto\-immune disease
  • and who have access to a \-20°C freezer
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 60
  • F.1\.3 Elderly (\>\=65 years) no

Exclusion Criteria

  • women will be excluded from participation in case of:
  • \-pregnancy
  • \-use of oral contraceptive pill
  • \-use of immunomodulatory drugs, antidiabetic drugs or anti\-inflammatory drugs on a daily basis
  • \-inflammatory bowel disease, autoimmune disease
  • \-(medical history of) pancreatitis

Outcomes

Primary Outcomes

Not specified

Similar Trials